IFN-beta is produced early in the response to viral infection as a direct output of TLR and RIG-I-like receptor (RLR) signaling, and it drives antiviral and immunomodulatory activity through the same Type I IFN receptor (IFNAR1/IFNAR2) used by IFN-alpha. Unlike IFN-alpha, which exists as more than a dozen subtypes, mouse IFN-beta is a single gene product; PBL offers it in four preparations that differ along two independent axes: expression system (mammalian cells vs. E. coli) and formulation (with carrier protein vs. carrier-free). When IFN-beta production is dysregulated, it has also been linked to pathological, disease-relevant signaling, and IFN-beta itself is used therapeutically in multiple sclerosis and, in some settings, cancer, both of which are studied extensively in mouse models.
Which Mouse IFN-Beta preparation should I use?
| If you need... | Consider |
|---|---|
| The closest match to native, glycosylated protein, with substantially higher specific activity than the E. coli-expressed line | Mouse IFN-Beta, Mammalian (12405-1) |
| The mammalian-expressed protein without a carrier, for in vivo dosing where carrier proteins could confound results | Mouse IFN-Beta, Mammalian, Carrier-Free (12410-1) |
| A well-established, frequently cited non-glycosylated reference protein | Mouse IFN-Beta, E. coli (12400-1) |
| A carrier-free preparation of the E. coli line specifically, not the mammalian one | Mouse IFN-Beta, Carrier-Free (12401-1) |